Enanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The firm had revenue of $18.00 million for the quarter, compared to the consensus estimate of $22.74 million. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Trading Up 9.1 %

NASDAQ:ENTA opened at $15.17 on Friday. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $37.14. The stock has a market cap of $320.94 million, a price-to-earnings ratio of -2.31 and a beta of 0.54. The stock has a 50-day moving average price of $14.92 and a two-hundred day moving average price of $11.98.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ENTA shares. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 6th. JPMorgan Chase & Co. decreased their price objective on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.33.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.